Vishy Pingali
@VishyPingali
Associate Professor in #Economics area @IIMAhmedabad. Views are personal.
3 Following 512 Followers 40 Posts
Latest posts 5
Looking forward to participating in this event!
Please mark the date for the 1st Asia Pacific E-Commerce Policy Summit jointly organized by @ICRIER, @UNESCAP, and @MSLGROUP_India. The event will be attended by senior policymakers, academics, and industry and legal experts from APAC.
#AsiaPacificECommerceSummit #ICRIERView quoted post on X
Looking forward to a fruitful partnership
🚨 #Announcement
The Dialogue is honored to welcome Dr. Viswanath Pingali as our esteemed Senior Fellow - Economics.
Dr. Viswanath Pingali, an Associate Professor at IIM Ahmedabad, excels in research on competition law, digital markets, and public health. He teaches microeconomics, game theory, and behavioral economics at IIMA, while also consulting for corporations and law firms.
With a Master’s from the Indian Statistical Institute and a PhD from Northwestern University, Prof. Pingali brings rich academic expertise to his role as a Senior Fellow - Economics at The Dialogue, focusing on competition law and policy.
Welcome to The Dialogue, Dr. Viswanath Pingali.
➡ 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗮𝗯𝗼𝘂𝘁 𝗗𝗿. 𝗣𝗶𝗻𝗴𝗮𝗹𝗶 𝗵𝗲𝗿𝗲: thedialogue.co/our-team/dr-vi…
#competitionlaw #competitionpolicy #seniorfellow
@VishyPingali | @kazimriz | @sakshammalikk | @Bhoomika106 | @IIMAhmedabadView quoted post on X
How costly is TB? A paper with @MeredithBBrooks, Tom Nicholson and @s_keshavjee
bmjopen.bmj.com/content/13/12/…
bmjopen.bmj.com Cost of inaction: a framework to estimate the economic cost of missing a patient with tuberculosis... Objectives To estimate the economic impact of failure to find and treat tuberculosis disease and prevent tuberculosis infection from progressing to active disease. Design Estimating the economic cost... bmjopen.bmj.com/content/13/12/…
Rare diseases represent, what economists like to call, market failure. So, we need to figure out better policies to address this problem...
#REDRESS also included Panel discussions on the Rare Disease Policy and Insurance, where insights on the recent National Rare Disease Policy, 2021 were shared and the challenges to claim insurance when diagnosed with rare diseases were discussed.View quoted post on X
